Immediate Impact
1 by Nobel laureates 48 standout
Citing Papers
Exploiting innate immunity for cancer immunotherapy
2023 Standout
Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?
2022 Standout
Works of Jan Štraub being referenced
ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) - Updated Efficacy and Safety
2020
PF608 ANCHOR (OP-104): A PHASE 1 STUDY UPDATE OF MELFLUFEN AND DEXAMETHASONE PLUS BORTEZOMIB OR DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS REFRACTORY TO AN IMID OR A PROTEASOME INHIBITOR
2019
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Jan Štraub | 153 | 100 | 129 | 37 | 315 | |
| Yiming Zhao | 108 | 76 | 73 | 41 | 337 | |
| G.-F. von Tempelhoff | 109 | 54 | 49 | 24 | 360 | |
| Xavier López‐Karpovitch | 234 | 58 | 48 | 45 | 345 | |
| Elif Gülsüm Ümıt | 93 | 67 | 68 | 44 | 264 | |
| Elif Suyanı | 160 | 115 | 76 | 41 | 370 | |
| Bircan Sönmez | 63 | 64 | 34 | 41 | 325 | |
| Eapen K. Jacob | 139 | 39 | 41 | 37 | 317 | |
| Ebru Koca | 162 | 102 | 57 | 34 | 324 | |
| Jean Chidiac | 60 | 68 | 62 | 23 | 358 | |
| Masato Moriyama | 73 | 45 | 60 | 33 | 290 |
All Works
Loading papers...